Gibbons CJ
Schering-Plough, Welwyn Garden City, UK OBJECTIVES: The Welsh National Database on Substance Misuse (WNDSM) has recorded around 1000 new referrals per quarter for patients requiring treatment for their opioid abuse problem with little evidence to suggest that numbers are declining. Opioid dependence in Wales is currently mostly treated with buprenorphine (Subutex) and methadone. Both of these therapies have their associated problems, notably the diversion of buprenorphine to the black market and its abuse through crushing, dissolving and injecting. The cost-effectiveness of buprenorphine/ naloxone (Suboxone), a formulation of buprenorphine containing a component to deter abuse, has been appraised in Scotland but not in Wales. METHODS: A decision analytic model was developed to evaluate the cost-effectiveness of buprenorphine/naloxone in the Welsh treatment setting. Clinical data were sourced from an unpublished trial comparing buprenorphine/naloxone and methadone as well as from a long-term safety trial of buprenorphine. The model takes into account expected pharmacy costs of dispensing and supervision. The base case assumed that buprenorphine/ naloxone would be supervised less frequently than methadone or buprenorphine due to its reduced potential for abuse. RESULTS: The base case analysis found buprenorphine/naloxone to be costeffective compared with methadone (ICER £26,775/QALY), and dominant compared to buprenorphine which is priced identically. Since all three treatment options have similar efficacy, these findings are attributable mainly to the reduced need for supervision of buprenorphine/naloxone compared to other substitution therapies. CONCLUSIONS: As was found in the Scottish system, buprenorphine/naloxone appears to be a cost-effective treatment option compared to methadone and buprenorphine alone. : 223, 207, 219, 198, 186, 188; number functional stable days: 152, 142, 146, 112, 106, 113 for paliperidone, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole, respectively. ICER values are of 6.85€/stable day; €10.03/ functional stable day; €478.70/prevented relapse for paliperidone. One-way sensitivity analyses prove that results of the study are strong. CONCLUSIONS: In the long-term treatment of schizophrenia, paliperidone is the dominant therapy in comparison to quetiapine, ziprasidone and aripiprazole. Compared to risperidone and olanzapine, it is the cost-effective therapy option.
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